CareDx (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the launch of HeartCare, a comprehensive rejection surveillance solution for heart transplant recipients.

As quoted in the press release:

“HeartCare gives physicians and patients access to otherwise invisible information, indicators of both their immune system activity and graft health,” said Peter Maag, CEO of CareDx. “With AlloMap, clinicians have more than a decade of clinical experience and with AlloSure, we gain additional insights from donor-derived cell-free DNA testing. We are fulfilling our promise to make sequencing based information available to the transplant clinic, now also for heart transplant patients.”

Click here to read the full press release.